← Today’s ReceiptsSource pending
Public-record receiptR-GASource pending
Rick Allen disclosed SELL $ABT
Here’s the public record: who traded, what they disclosed, when it happened, how late it appeared, and what context is attached.
Trade range
$15K – $50K
Filed
2026-06-05
Trade date
2026-04-16
Disclosure lag
50 days after trade
Why this receipt matters
A quick read before you share it.
These are factual context points from the receipt and linked public-record data. They explain why the disclosure may be worth opening, not whether anyone acted improperly.
1The disclosure is tracked with source status pending, so treat it as a record to verify rather than a finished source trail.
2The filing appeared 50 days after the trade date, beyond the standard 45-day STOCK Act window.
3The disclosed range is $15K – $50K, which is the public reporting band rather than an exact profit or loss figure.
414 nearby same-ticker disclosures appeared in the surrounding 30-day window.
5Committee context is available for Rick Allen, but PoliWealth treats it as context - not proof of intent or wrongdoing.
6Related public-record context includes 19 lobbying filings and 44 federal contract records.
Source
source pending
Source: indexed congressional disclosure; official source link pending · filed 2026-06-05 · disclosed 50d after transaction
Market context
ABT
Vs SPY: -13.4%
Factual flags
- Filed after the standard 45-day STOCK Act window.
- 19 lobbying filings linked to this ticker.
- 44 federal contract records linked to this ticker.
- 14 nearby same-ticker disclosures in the surrounding 30-day window.
- Traded ABT 4d before lobbying filing by ABBOTT LABORATORIES ($1,410,000) (committee overlap: Healthcare)
- Traded ABT 16d after federal contract with Department of Veterans Affairs ($3,378,771)
- 7 trades filed on 2026-06-05 (batch dump)
- Filed 50 days after transaction (STOCK Act limit: 45)
Member trail
Rick Allen
U.S. House · GA-12
House Committee on Energy and CommerceHouse Committee on Education and Workforce
Ticker trail
$ABT
Company metadata pending
Follow this tickerAlert me when this ticker gets a new congressional receipt. This page reports public disclosures and factual context only. It does not determine intent, is not an accusation, and is not investment advice.